Commercial Agreement Explores Use of NASA Biotechnology
NOTE TO EDITORS: N00-42
NASA Administrator Daniel S. Goldin will announce on Thursday an
unprecedented private sector investment in NASA biotechnology,
which is expected to open the door to a new frontier in medical
research. This unique licensing agreement may one day lead to new
treatment options for patients who today face organ transplant
surgery.
The research coming from this groundbreaking agreement may also
offer other benefits, such as faster drug testing and approval,
and the ability to fight dangerous diseases more effectively. The
agreement for commercial use of NASA’s Bioreactor technology will
be signed by Goldin on Thursday, Sept. 14.
This first-of-its-kind accord results from a three-year
collaboration between NASA and a private venture capital company.
The joint effort involved an extensive market-driven study of both
what was technically possible and most likely to be commercially
successful.
The signing will begin at 1 p.m. EDT Thursday in Room SC-6 of the
U.S. Capitol Building. Representatives from the venture capital
firm and a newly established biotech joint venture company, along
with Goldin and others, will discuss the agreement and present a
video explaining the Bioreactor technology and its potential.
Media representatives are invited to attend the signing.
– end –